Clarification of the statement in the interim report published 19 July 2019 regarding the rights issue with pre-emptive rights

Karo Pharma Aktiebolag (”Karo Pharma”) today published its interim report for the period January – June 2019. On page 2 of the Swedish language version of the interim report, it was, slightly misleadingly, stated that a directed rights issue of approximately MSEK 1,500 with pre-emptive rights for the shareholders of Karo Pharma is planned.

Karo Pharma hereby wants to clarify that the rights issue, in accordance with what has been previously published through a press release on 21 June 2019 relating to the acquisition of Trimb, will be a rights issue with pre-emptive rights and that those who are shareholders as of the record date will be entitled to participate in the rights issue with pre-emptive rights.
  

For further information, please contact

Christoffer Lorenzen, CEO, +46 73 501 76 20, christoffer.lorenzen@karopharma.se
Mats-Olof Wallin, CFO, +46 76 002 60 10, mats-olof.wallin@karopharma.se
    

About Karo Pharma

Karo Pharma is a specialty pharma company that develops and markets products to pharmacies and directly to healthcare providers. The share is listed on Nasdaq Stockholm in the Mid Cap segment.
  

The information was submitted for publication, through the agency of the contact person set out above, on July 19, 2019 at 16:00 p.m. CET.

Related documents

Press release (PDF)